• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

PHAR

Partnership for Health Analytic Research

  • Services
    • Economic Modeling
    • Real World Data: Secondary Data Analysis
    • Evidence Synthesis
    • Real World Data: Primary Data Collection
  • Publications
  • Clients
  • Team
  • News
  • Contact

Primary Sidebar

News Categories

  • Presentations & Events
  • Awards & Recognition
  • Publications
  • News & Announcements

Archive

  • 2022
  • 2021
  • 2020
  • 2019

Low Adherence to Dornase Alfa in Patients with Cystic Fibrosis

Patients with cystic fibrosis (CF), a common life-shortening inherited disorder, often don’t take all their medications. It has been proposed that better adherence could improve these patients’ health more than any specific medical treatment. Investigators at PHAR, LLC, in collaboration with Genentech, Inc. conducted a retrospective cohort analysis and confirmed that there was generally low adherence to dornase alfa, a key drug for CF. The study also found that better adherence was associated with shorter hospital stays. This publication can be viewed by visiting the Journal of Medical Economics website.

April 16, 2013 | Publications

Partnership for Health Analytic Research

Beverly Hills
Cambridge
San Francisco
info@pharllc.com
310.858.9555
pharllc.com
  • Employment
  • Contact
  • Privacy Policy
Design by Studio Rainwater
© PHAR 2022